The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
HOME > ORGANIZATION
ORGANIZATION
- Price Gap between Long-Listed Products, Generics Necessary: FPMAJ Chairman Naito
October 11, 2012
- President Teshirogi of JPMA Stresses Need for Asian Countries to Cooperate in Drug Discovery
October 11, 2012
- Proposal to Unify Basic Dispensing Fees Could Be Taken Up Again: JPA Vice President Miura
October 10, 2012
- Life Science Budget in Japan Lacks Absolute Amount: JPMA President Teshirogi
October 10, 2012
- “Industry Also Needs to Consider” Distribution of Drug Expenditure: Former Administrative Vice Minister of Health Erikawa
October 5, 2012
- Enterprise Integration Has Not Yet Advanced among Drugmakers in Japan: Former JFTC Chairman Takeshima
September 27, 2012
- MHLW to Announce 14 New Examples of Approved Off-Label Drug Use Based on 1980 Notification in Near Future
September 26, 2012
- Risk for 7 Main Diseases Increases at Age 63: Anti-Aging Laboratory
September 25, 2012
- JPA Issues Notice on Prohibition of Dispensing Point Services, “Not Intended as Transitional Measure”
September 25, 2012
- Wholesale Industry FTC’s Liaison Conference on Ending Provision of Free Benefits and Labor to Hold 1st Meeting in October
September 25, 2012
- MHLW Reports Results of Analysis of “Close-Call” Incidents at Pharmacies with Generics
September 24, 2012
- Mr Hayashi of OPIR Stresses Need for Approval and Reimbursement of More Companion Diagnostics
September 21, 2012
- Dr Fukuda Lays Out 4 Options for HTA Introduction in Drug Pricing
September 20, 2012
- Anti-Japanese Demonstrations in China Have Had “Absolutely No Effect” on Takeda: President Hasegawa
September 20, 2012
- Maker FTC Bans Drink Donations at Academic Conferences
September 19, 2012
- Iyakuhin Renmei to Break Up to Create Unified Pharmaceutical Industry Labor Union
September 14, 2012
- 35% of Domestic Drug Makers Do Not Conduct First-in-Human Trials in Japan: JPMA Survey
September 5, 2012
- Dr Teshirogi of JPMA Comments on Govt’s Efforts to Promote Regulatory Science; Expresses Concerns About Japan’s Future as Drug-Originating Country
September 5, 2012
- Total Number of MRs Up 4.3% at 63,875, Marking Largest Number in History: MR White Paper
September 5, 2012
- JGA Fails to Achieve Goal of Eliminating “Out-of-Stock” Products Yet Again
August 31, 2012
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…